Cancer Biomarkers Market Size, Share, Regional Growth, 2026-2034
- jhon smith
- May 11
- 3 min read
Market OverviewAccording to fortune business insights, The global cancer biomarkers market size was valued at USD 42.87 billion in 2025. The market is projected to grow from USD 48.2 billion in 2026 to USD 83.61 billion by 2034, exhibiting a CAGR of 7.13% during the forecast period. North America dominated the cancer biomarkers market with a market share of 35.94% in 2025.Fortune Business Insights™ has deep-dived into these insights in its latest research report, titled “Cancer Biomarkers Market, 2026-2034.”The analysis shows that top companies are investing more in cancer biomarkers due to the increasing global incidence of cancer, expanding use of biomarkers in drug development, and significant technological advancements. This trend indicates a strong and growing demand for cancer biomarkers worldwide for applications in diagnostics, prognostics, and personalized medicine.
Major Players Profiled in the Market Report:
F. Hoffmann-La Roche Ltd.
Abbott
Thermo Fisher Scientific
Bio-Rad Laboratories, Inc.
CENTOGENE N.V.
Axon Medchem
Sino Biological Inc.
R&D System
BioVision Inc.
Myriad RBM
SegmentsHigh Global Incidence to Propel Breast Cancer Segment GrowthBased on cancer type, the market is divided into breast cancer, lung cancer, colorectal cancer, prostate cancer, and others. The breast cancer segment holds the largest market share and dominates the market owing to its high global prevalence and rising awareness about early diagnosis, which has led to a large patient pool undergoing diagnostic tests.
Rising Breast Cancer Prevalence to Drive HER-2 Biomarker Segment ExpansionBy biomarker type, the market is categorized into PSA, HER-2, EGFR, KRAS, and others. The HER-2 segment is leading the market, driven by the high prevalence of breast cancer and the increasing introduction of new biomarker-based tests, such as liquid biopsies, for its diagnosis.
Diagnostics & Research Laboratories to Dominate the Market Due to High Volume of TestingBased on end-user, the market is segmented into pharmaceutical & biotechnology companies, diagnostics & research laboratories, hospitals & specialty clinics, and others. The diagnostics & research laboratories segment holds the largest market share owing to the high volume of tests performed and the continuous introduction of new diagnostic products by key players.
Report CoverageThe report offers:
Major growth drivers, restraining factors, opportunities, and potential challenges for the market.
Comprehensive insights into regional developments.
List of major industry players.
Key strategies adopted by the market players.
The latest industry developments include product launches, partnerships, mergers, and acquisitions.
Drivers & RestraintsRising Prevalence of Cancer to Propel Market GrowthThe rapid growth in the global prevalence of cancer is a primary driver for the market, leading to an increased demand for early disease diagnosis and personalized treatment. The rising adoption of biomarkers in companion diagnostics, disease risk assessment, and drug discovery is boosting the cancer biomarkers market growth.However, the lack of reimbursement policies for biomarker testing in many countries and the high cost of diagnosis and treatment may hamper market growth, limiting the number of patients who undergo testing.
Regional InsightsHigh Cancer Prevalence and R&D Investment Propels Market Growth in North AmericaNorth America holds the dominant cancer biomarkers market share and is projected to experience significant growth. The region’s growth is attributed to high cancer prevalence, a well-established regulatory framework, the rapid adoption of advanced technologies, and extensive use of biomarkers in drug discovery and personalized medicine.Asia Pacific is one of the fastest-growing regions in the market. The growth is attributed to the accelerating uptake of biomarker-based diagnostics, increasing public and private investment in oncology research, and a rising emphasis on personalized medicine.
Cancer Biomarkers Market Future Growth:The cancer biomarkers market is experiencing robust growth, fueled by the rising global incidence of cancer, a paradigm shift toward personalized medicine, and significant technological advancements in diagnostics. Today's healthcare providers are increasingly relying on biomarkers for early detection, accurate diagnosis, prognosis, and selecting targeted therapies. There is a growing demand for non-invasive diagnostic tools like liquid biopsies and an expanding use of biomarkers in drug discovery and development. The rapid expansion of healthcare infrastructure and rising R&D investment in emerging markets are also key growth drivers. While North America continues to dominate, the Asia-Pacific region is seeing a surge in demand, driven by increasing healthcare expenditure and a growing focus on early cancer detection.
Competitive LandscapeGrowing Adoption of Strategic Collaborations and Product Launches to Propel Market GrowthThe market features prominent players like F. Hoffmann-La Roche Ltd., Abbott, and Thermo Fisher Scientific, Inc. These leading companies are accelerating growth through strategic initiatives such as introducing novel biomarker tests, entering into research collaborations, and pursuing mergers and acquisitions. Their proactive approach to innovating and expanding their diagnostic portfolios continues to fuel the market’s momentum.
Key Industry Development
March 2021: Roche announced it received FDA approval for the VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify patients eligible for LORBRENA, a targeted cancer treatment.
July 2020: Thermo Fisher Scientific announced a companion diagnostic (CDx) agreement with Chugai Pharmaceutical Co., Ltd. to expand the use of its Oncomine Dx Target Test in Japan for non-small cell lung cancer (NSCLC) patients.
Comments